Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
出版年份 2015 全文链接
标题
Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
作者
关键词
-
出版物
CELL CYCLE
Volume 14, Issue 8, Pages 1252-1259
出版商
Informa UK Limited
发表日期
2015-05-07
DOI
10.1080/15384101.2015.1014149
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
- (2015) Filip Janku et al. Oncotarget
- Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
- (2015) Jennifer Wheler et al. Oncotarget
- Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer
- (2014) Hanna K. Sanoff et al. JNCI-Journal of the National Cancer Institute
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
- (2014) Filip Janku et al. Cell Reports
- The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis
- (2013) X Xing et al. BRITISH JOURNAL OF CANCER
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
- (2013) Monica M. Mita et al. Clinical Breast Cancer
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
- (2013) Andrea Rocca et al. EXPERT OPINION ON PHARMACOTHERAPY
- Extra-cell cycle regulatory functions of cyclin-dependent kinases (CDK) and CDK inhibitor proteins contribute to brain development and neurological disorders
- (2013) Takeshi Kawauchi et al. GENES TO CELLS
- Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy
- (2012) J. J. Wheler et al. ANNALS OF ONCOLOGY
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?
- (2012) Jennifer N. Wu et al. Cancer Discovery
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients
- (2011) I. Iacobucci et al. CLINICAL CANCER RESEARCH
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started